



8th International Hematologic Malignancies Conference: Bridging the Gap 2017
JANUARY 12-14, 2017. BANGKOK, THAILAND

CONFERENCE BROCHURE

Dear Colleagues and Friends,

As the conference chairs of the **8th International Hematologic Malignancies Conference: Bridging the Gap 2017 (BTG2017)**, scheduled for **JAN 12-14, 2017** in **BANGKOK, THAILAND**, it is our pleasure to invite you to participate in this unique and premier event. Here you will have an opportunity to align with the premier conference dedicated to hematology/oncology specialists from around the globe. (Conference website: www.aphcon.org/btg2017).

BTG2017 is one of the largest and most important conferences to be held in the **Asia Pacific region** concerned with the research and treatment of hematologic malignancies. More than 300 hematologic malignancy experts are expected to attend the three-day conference.

There are many opportunities for industry to support the conference's educational programs, annual meeting materials and services, such as tradeshow exhibition, satellite symposium participation, exclusive supporter options and others. Each opportunity promises to provide a significant presence for companies during the conference.

We thank you for your support and considerations.



*Richard Champlin
Co-Chair BTG2017*



*Morton Coleman
Co-Chair BTG2017
Founder, The Medal Group*



*Surapol Issaragrisil
Co-Chair BTG2017
President, APHCON*



*Wichai Prayoonwiwat
Co-Chair BTG2017
President, Thai Society Hematology*



*Xiao Jun Huang
Executive Director, APHCON*



*Kaiyan Liu
Secretary, APHCON*



*Simrit Parmar
Scientific Director, APHCON*

TABLE OF CONTENTS

APHCON	3
Executive summary	3
- Program description	3
- What is G.A.P?	4
- Overview	4
- Goals	4
BTG2017	5
- BTG2017 educational objectives	5
- BTG2017 scientific committee	6
Need assessment BTG2017	7
1. Orientation to purpose and scope of the agenda:	7
2. How it is different	8
3. Strategic value is to supporters	8
4. Most important topics for the target audience	9
5. Confirmation of facility resources for sponsorship: exhibit space specs, available rooms and capacity for ancillary activities	9
6. Description of target audience, current registration, and demographics	10
BTG2017 scientific agenda	11
- Day 1 (January 12, 2017)	11
- Day 2 (January 13, 2017)	13
- Day 3 (January 14, 2017)	15
Plan of action	16
Corporate support opportunities	18
Exhibit booth details	20
Organizing partner	20

APHCON

The APHCON (Asia-Pacific Hematology Consortium: www.aphcon.org) is the official host of BTG2017 and presents the 8th International Hematologic Malignancies Conference with our logistics partner, The Medal Group. Founded in 2007, the Society is a non-profit medical association committed to promoting discourse about and furthering the research of hematology.

EXECUTIVE SUMMARY

After the great success of BTG2016, we present the 8th International Hematologic Malignancies Conference to be held on Jan 12-14, 2017 in Bangkok, Thailand. The Congress brings together leading authorities in Hematology Oncology to present the latest ground breaking findings on cutting edge research and novel treatments. The discussion forums provide an opportunity to integrate the latest pharmaceutical interventions. The conference targets hematologic malignancies in particular leukemia, lymphoma, and myeloma. The target audience is Southeast and Central Asia, Japan, Australia.

PROGRAM DESCRIPTION

New exciting and complex therapeutics for hematologic malignancies are coupled with recognizable educational gaps. We propose a novel educational program that will use mobile application learning in combination with the traditional live educational activity.

What is G.A.P?

Global Academic Programs (GAP) facilitates and administers MD Anderson's Sister Institution Network; the largest global network of cancer centers working collaboratively on research and education aimed at lessening the world's cancer burden. You can stay informed by subscribing to GAP Connect, a weekly newsletter intended to engage and enable global collaborations in cancer research.

OVERVIEW

Cancer is a leading cause of death in central and Southeast Asia. Hematologic malignancies are an increasing subset of the total cancer incidence rate. In the recent years great improvement in the field of Oncology has taken place with a rapid growth in trained oncologists and cancer centers. However, since the Asian healthcare community is geographically dispersed, it is often characterized by a lack of standardization of treatment and different philosophies of care. Given this fragmentation, there is a need to formalize and integrate conceptual knowledge, disease understanding, therapeutic agent intervention, supportive care, and management of complications.

Since Thailand is on the leading edge of medicine and especially oncology care, it is an ideal venue for promoting stronger ties between practitioners and researchers from different countries and providing a platform for advancing daily clinical practice. This would in turn improve overall quality of cancer treatment, especially in countries that do not have guaranteed access to the latest breakthroughs.

Our ultimate goal is to help improve the quality of patient care, set standards of clinical competence for practice and encourage the continuing scholarship required for professional excellence over a lifetime of service.

This Congress will be an important step towards implementing a new standard of care and uniformity of knowledge, which in turn will bring dividends to cancer patients, physicians and future practitioners.

GOALS

1. Identify the existing need for the current medical education of the practicing hematologists with an Asian perspective, and build sessions to address the key areas of need.
2. Construct methodology for promoting increased awareness, knowledge and improved practice in the field of malignant hematology in the Asian sector including practice guidelines and the latest therapeutic agents.
3. Encourage and provide opportunity for clinical research in the field of malignant hematology.

BTG2017

This congress will be a productive, interactive and educational experience for the attendees. Top researchers and practitioners from the world over will meet to discuss the current state - and future directions - of Hematologic Malignancies in the Asian sector and explore opportunities for collaborations in order to further the field (conference website: www.aphcon.org/btg2017).

The event promises to be a unique medical education forum for the exchange of critical information as well as analyze the challenges faced by the practicing clinicians.

It will feature didactic presentations and debates, in which experts will discuss some of the most challenging topics in leukemia, stem cell transplant and mobilization, myelodysplastic syndrome, lymphoma and myeloma, providing a thorough analysis of research breakthroughs and emerging data.

BTG2017 EDUCATIONAL OBJECTIVES

1. Identify the existing need for the current medical education of the practicing hematologists with an Asian perspective, and build sessions to address the key areas of need.
2. Construct methodology for promoting increased awareness, knowledge and improved practice in the field of malignant hematology in the Asian sector including practice guidelines and the latest therapeutic agents.
3. Encourage and provide opportunity for clinical research in the field of malignant hematology.
4. Interactive workshops will provide active learning opportunity for the delegates. By using the methodology of digital audience response service and novel digital networking applications, it will provide a great conduit for information exchange.
5. Difficult case discussion: Speakers will be instructed to structure their topics around case presentations and interactive discussions. Such a format will encourage audience to identify and / or present their own challenges in clinical practice and potentially apply the clinical solutions discussed at the conference.

6. Academic and peer review process will be implemented in terms of the selection of the best oral abstract presentation. Delegates will submit their abstracts through the online process and selected posters will be displayed at the conference. Specifically, the best oral abstract will be presented at the conference.

BTG2017 SCIENTIFIC COMMITTEE

Xiao Jun Huang, Peking University, Beijing, China

Robert Orlowski, MD Anderson Cancer Center, Houston, USA

Borje Andersson, MD Anderson Cancer Center, Houston, USA

Kaiyan Liu, Peking University, Beijing, China

James Chim, University of Hong Kong

Raymond Wong, Chines University Hong Kong

Didier Blaise, University of Marseille, France

Simrit Parmar, MD Anderson Cancer Center, Houston, USA


Piyanuch Kongtim, Siriraj Hospital, Bangkok, Thailand

Vikram Mathews, CMC, Vellore, India

Young Ho Lee, Hanyang University College of Medicine, Seoul, S. Korea

1. Orientation to purpose and scope of the agenda:

Why the Project exists: Cancer is a leading cause of death in central and Southeast Asia. It is important to note that in most developed countries, cancer is the second largest cause of death after cardiovascular disease, and epidemiological evidence points to this trend emerging in the less developed world. This is particularly true in countries in "transition" or middle-income countries, such as in South America and Asia. Already more than half of all cancer cases occur in developing countries. Cancer alone accounts for 16% of all deaths in Asia and Hematologic malignancies are an increasing subset of the total cancer incidence rate.



In the recent years great improvement in the field of Oncology has taken place with a rapid growth in trained oncologists and cancer centers as well as advancements in diagnostic technology. However, since the Asian healthcare community is geographically dispersed, it is often characterized by a lack of standardization of treatment and different philosophies of care.

Given this fragmentation, there is a need to formalize and integrate conceptual knowledge, disease understanding, therapeutic agent intervention, diagnostic methodologies, supportive care, and management of complications.

Since Bangkok, Thailand is on the leading edge of medicine and especially oncology care, it is an ideal venue for promoting stronger understanding between practitioners and laboratory researchers from different fields and providing a platform for advancing daily clinical practice. This would in turn improve overall quality of cancer treatment, especially in terms of diagnosis and follow up of therapeutic strategies.

The proposed conference ‘8th International Hematologic Malignancies Conference ‘Bridging the Gap:2017’ in Bangkok, Thailand to be held on Jan 12-14, 2017 is the result of the joint effort of the MD Anderson cancer Center, Houston and Siriraj Hospital, Bangkok, Thailand.

The key objective of this meeting is to lay foundation of a potentially growing relationship between US and South-East Asia in the field of malignant Hematology.

2. How it is different:

This is a unique conference where US and Asian speakers will share the same platform to address the local physicians and fellows in training. Create awareness regarding the disease concept, pathology, diagnosis, new therapeutic options and novel pharmaceutical interventions. This conference also, proposes to have open case discussions where the local physicians will get a chance to do case discussions in an open forum platform set up.

This informal setting proposes to overcome any barriers and provide a conduit of open discussion, exchange of ideas, sharing of data and possible clinical collaborations. This congress will be an exciting, productive, interactive and educational experience for the attendees. Top researchers and practitioners from the world over will meet to discuss the current state – and future directions – of Hematologic Malignancies in the Asian sector and explore opportunities for collaborations in order to further the field. The event promises to be a unique medical education forum for the exchange of critical information as well as analyze the diagnostic and therapeutic challenges faced by the practicing clinicians. It will feature didactic presentations and debates, in which experts will discuss some of the most challenging topics in lymphoma, myeloma, immunotherapy and stem cell transplant, providing a thorough analysis of research breakthroughs and emerging data.

3. Strategic value is to supporters:

Bangkok, Thailand has one of the fastest growing economies with a great opportunity for the pharmaceutical industry. Moreover, Thailand is very friendly to visitors and foreign nationals. It is very easy to travel to, easily accessible, strategically located in the center of Asia and Australia. By providing an educational platform, our supporters will gain an extra ordinary advantage over the competitors in terms of getting great exposure, able to deliver the updated data as well as educate the prescribing physicians about their product. Moreover, the conference will provide a unique and credible interaction with the meeting delegates in order to establish long term relationships.

By supporting one of the biggest and the first truly international Hematologic Malignancies Conference in South East Asia, the sponsors get exposure to over 500 attendees, most of who are from China, India, Australia, Japan, Malaysia, Thailand, Vietnam, Indonesia, Taiwan, UAE, UK, Middle East, and the United States. The sponsors get an opportunity to support promotional luncheons and dinner symposiums. Also, there is opportunity for exhibit booths, where the sponsors are able to directly get in touch with the local oncologists which otherwise maybe onerous. Therefore, with one contribution, the pharmaceutical companies are able to really get a return on their investment by getting a tremendous exposure, advertisement, marketing opportunity, gather demographic data, educate the practicing oncologists regarding their latest innovations and possibly get access to other wise hard to reach physicians.

4. Most important topics for the target audience:

The incidence and prevalence of Hematologic Malignancies are on a great increase in Asia. The proposed topics cover the pathology, diagnostic procedures and latest treatments including stem cell transplant and post-transplant maintenance therapy. There is also discussion of novel therapies including vaccine therapy for Lymphoma and graft manipulation for myeloma. Most of all the speakers are internationally acclaimed and of great repute. These are topics that need in depth education and understanding and since these diseases are on the rise, it gives the target audience a great resource to learn from the major thought leaders in the field.

5. Confirmation of facility resources for sponsorship: exhibit space specs, available rooms and capacity for ancillary activities:

BTG2017 will be held at the **Swissôtel Le Concorde Hotel**. 204 Rachadapisek Road, Huay Kwang ▪ Bangkok 10320 ▪ Thailand. Tel: +66 2694 2222 ▪ Fax: +66 2694 2218 ▪ E: reservation.bangkok@swissotel.com . The 22-storey hotel offers travellers affordable luxury with 407 elegantly spacious rooms and suites and impeccable Swiss hospitality. The top four floors of the hotel are devoted to the Executive Club rooms, which offer complimentary access to the lounge with an exclusive breakfast buffet, evening cocktails, private meeting space and an Executive fitness centre. Featuring truly amazing meeting and convention facilities, Swissotel Le Concorde Bangkok offers 3,411 m² of meeting space. Attendees will be offered subsidized group rate at the conference venue

6. Description of target audience, current registration, and demographics:

This conference is specifically designed for Hematologists, Oncologists, Transplant Oncologists, Radiation Oncologists, physicians-in-training, and healthcare professionals (nurses, pharmacists, etc.) involved in and/or interested in hematologic malignancies and their management. Attendees are expected to be from China, India, Hong Kong, Australia, Japan, Malaysia, Thailand, Vietnam, Indonesia, Taiwan, UAE, UK, Middle East, and the United States. The current pre-registration estimated number is around 400. This number is generated by the preliminary response to the 'Save the Date' emails and advertisements. The presence of US faculty is the key to ensuring robust attendance. Most of the physicians are being sponsored by the local universities and hospitals. The registration and meeting delegates' attendance will be acquired by peer to peer advertisement, journal advertisements, Flyer distribution into universities and hospitals, email newsletters etc.

BTG2017 SCIENTIFIC AGENDA

Day 1. January 12, 2017

8:00 AM INAUGURATION AND OPENING SPEECH

Dr Surapol Issaragrisil (President, APHCON); Dr Richard Champlin; Dr Morton Coleman; Dr. Wichai Prayoonwiwat (President, TSH)

8:30 AM: B-CELL LYMPHOMA

Moderator: Surapol Issaragrisil (Thailand); Richard Champlin (USA)

Revised Classification, New Diagnostic Criteria for Non-Hodgkin's Lymphoma

Pei Lin (USA) (20 min)

Allogeneic Stem Cell transplantation for Lymphoma (includes Hodgkin's Lymphoma)

Didier Blaise (France) (30 min)

Immunotherapy for B-Cell Lymphoma (includes cell therapy)

Frederick Hagemeister (USA) (30 min)

10:00 AM: Coffee Break and Poster viewing

10:30 AM: T-CELL LYMPHOMA

Moderator: Wichai Prayoonwiwat (Thailand), Adolfo de la Fuente (Spain)

Advances in Peripheral T cell Lymphoma

YL Kwong (Hong Kong) (20 min)

NK/T Cell Lymphoma

Weili Zhao (China) (20 min)

Angio-Immunoblastic T Cell Lymphoma

Daryl Tan (Singapore) (20 min)

Role of Transplant in Lymphoma

Nobert-Claude Gorin (France) (20 min)

12:00 PM LUNCH

1:00 PM HODGKIN'S LYMPHOMA

Moderator: Noppadol Siritanaratkul (Thailand), Frederick Hagemeister (USA)

Newly Diagnosed HL

Adolfo de la Fuente (Spain) (15 min)

PET Monitoring for Response and Therapy Decisions

Pankaj Malhotra (India) (15 min)

Relapsed Hodgkin Lymphoma

Frederick Hagemeister (USA) (15 min)

2:00 PM DIFFUSE LARGE B CELL LYMPHOMA

Moderator: Suporn Chuncharunee (Thailand), Govind Babu (India)

Diagnosis and Treatment: Newly diagnosed DLBCL

Hemant Malhotra (India) (15 min)

Approach to Primary Treatment Failure

Archrob Khuhapinant (Thailand) (15 min)

Post Auto-Stem Cell Transplant Relapse

Nobert-Claude Gorin (France) (15 min)
Management of CNS involvement in DLBCL
Govind Babu (India) (15 min)

3:00 PM - 3:30 PM COFFEE BREAK

3:30 PM LOW GRADE LYMPHOMA

Moderator: Wanchai Wanachiwanawin (Thailand), Daryl Tan (Singapore)

Newly Diagnosed Follicular Lymphoma: Chemo- vs. Targeted Therapy?

Daryl Tan (Singapore) (15 min)

MRD and Maintenance Therapy for FL

Ashok Vaid (India) (15 min)

Stem Cell Transplant for FL

Adolfo de la Fuente (Spain) (15 min)

Newly Diagnosed Mantle Cell Lymphoma

Hui Qiang Huang (China) (15 min)

4:30 PM CHRONIC LYMPHOCYTIC LEUKEMIA

Moderator: Ponlapat Rojnuckarin (Thailand), Raymond Wong (Hong Kong)

Novel Targeted Therapies for CLL

Colin Phipps (Singapore) (15 min)

Cell Therapy for CLL

Frederick Hagemeister (USA) (15 min)

Maintenance Therapy in CLL

Raymond Wong (Hong Kong) (15 min)

5:30 PM DINNER SYMPOSIUM

BTG2017 SCIENTIFIC AGENDA

Day 2. January 13, 2017

8:00 AM ACUTE MYELOID LEUKEMIA

Moderator: *Borje Andersson (USA) and Kaiyan Liu (China)*

Ideal induction therapy for newly diagnosed AML. Do we have a consensus?

Jie Jin (China) (20 min)

Decision analysis of post remission therapy for intermediate risk AML

Kanadit Prayongratana (20 min)

Allogeneic Stem cell transplant in CR1 for t(8;21) AML

Xiao Jun Huang (China) (20 min)

Advances in treatment for Elderly AML

William Hwang (Singapore) (20 min)

9:30 AM KIAN ANG MEMORIAL LECTURE

Moderator: *Borje Andersson (USA) and Panya Seksan (Thailand)*

Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink?

Present status and future prospects

Robert-Claude Gorin (France) (25 min)

10:00 AM BEST ORAL ABSTRACT PRESENTATION

Moderator: *Frederick Hagemeister (USA) and Vikram Mathews (India)*

Top 2 selected abstracts at 10 minutes each

10:30 AM Coffee Break and poster Session

11:00 AM ACUTE LYMPHOCYTIC LYMPHOMA

Moderator: *Xiao Jun Huang (China) and William Hwang (Singapore)*

Update on Allogeneic Stem Cell Transplant in ALL

Sachiko Seo (Japan) (20 min)

CAR19 - T Cell Adoptive Therapy for B-ALL

Xiangyu Zhao (20 min)

Personalized therapy in Pediatric ALL

Allen Yeoh (Singapore) (20 min)

12:00 PM LUNCH

1:00 PM APLASTIC ANEMIA

Moderator

Surapol Issaragrisil (Thailand) and Pankaj Malhotra (India)

Non transplant therapies

Suporn Chuncharunee (Thailand) (15 min)

Donor selection and conditioning regimen

Richard Champlin (USA) (15 min)

Case Discussion

(15 min)

1:00 PM ACUTE MYELOID LEUKEMIA

Moderator

Artit Ungkanont (Thailand) and Weili Zhao (China)

Determining and Monitoring MRD

Pei Lin (USA) (15 min)

Biphenotypic AML

Suning Chen (China) (15 min)

FLT3 positive AML

Vikram Mathews (India) (15 min)

2:00 PM THALASSEMIA

Moderator

Suradej Hongeng (Thailand) and Borje Andersson (USA)

Iron overload and novel therapy

Vip Viprakasit (Thailand) (15 min)

Transplant updates

Suradej Hongeng (Thailand) (15 min)

Case Discussion

(15 min)

2:00 PM CHRONIC MYELOGENOUS LEUKEMIA

Moderator

Tontanai Numbenjapol (Thailand) and Hemant Malhotra (India)

Newly Diagnosed CML

Qiang Jiang (China) (15 min)

Relapsed CML

Dong Wook Kim (S. Korea) (15 min)

Allogeneic Stem Cell Transplant and NK Cell Therapy

Richard Champlin (USA) (15 min)

3:00 PM - 3:15 PM COFFEE BREAK

3:15 PM IMMUNE THROMBOCYTOPENIA

Moderator

Theera Ruchutrakool (Thailand) and Pankaj Malhotra (India)

How to treat newly diagnosed ITP

Raymond Wong (Hong Kong) (15 min)

Treatment of relapsed/ refractory ITP

Ponlapat Rojnuckarin (Thailand) (15 min)

Thrombocytopenic syndrome in pregnancy

Theera Ruchutrakool (Thailand) (15 min)

3:15 PM DONOR SELECTION

Moderator

Piyanuch Kongtim (Thailand), and Richard Champlin (USA)

Haplo vs. MUD

Borje S. Andersson (USA) (15 min)

Haplo vs. Cord

Didier Blaise (France) (15 min)

Managing Donor HLA Antibodies

Piyanuch Kongtim (Thailand) (15 min)

4:15 PM Hemophilia

Moderator

Ampaiwan Chuansumrit (Thailand) and Vikram Mathews (India)

Standard of care and assessment for hemophilia

Ampaiwan Chuansumrit (Thailand) (15 min)

Novel treatment using emcizumab

Keiji Nogami (Japan) (15 min)

Genetic Mutations in Hemophilia

Objoon Trachoo (Thailand) (15 min)

4:15 PM Graft versus Host Disease

Moderator

Udomsak Bunworasate (Thailand) and Suning Chen (China)

Post-Transplant Cy vs. ATG for Haplo Transplant

Didier Blaise (France) (15 min)

Risk Stratified Corticosteroids for Haplo

Transplant

Xiao Jun Huang (China) (15 min)

Cell Therapy for GVHD

Simrit Parmar (USA) (15 min)

5:30 PM APHCON PRESIDENT DINNER RECEPTION

BTG2017 SCIENTIFIC AGENDA

Day 3. January 14, 2017

8:00 AM: MULTIPLE MYELOMA: NEWLY DIAGNOSED

(Open forum with interactive Q and A session)

Moderator *Robert Orlowski (USA), Lalita Norasetthada (Thailand)*

Consensus guidelines for diagnosis and response.

Elisabet Esteve Manasanch (USA) (20 min)

Frontline Therapy for Transplant Eligible Patients: Doublet, Triplet, Quadruplet.

Robert Orlowski (USA) (20 min)

Autologous Stem Cell Transplant and Post-Transplant maintenance

Simrit Parmar (USA) (20 min)

Frontline Therapy for Transplant In-eligible patients.

Juan Li (China) (20 min)

9:30 AM COFFEE BREAK

10:00 AM: MULTIPLE MYELOMA: RELAPSED

(Open forum with interactive Q and A session)

Moderator *James CS Chim (Hong Kong), Weerasak Nawarawong (Thailand)*

Defining Relapse: Biochemical vs. symptomatic. When to increase the dose? When to switch therapy?

Elisabet Esteve Manasanch (USA) (20 min)

Choice of Therapy for Relapsed Myeloma.

James CS Chim (Hong Kong) (20 min)

Changing Landscape of Myeloma Therapy: Focus on Proteasome Inhibitors.

Robert Orlowski (USA) (20 min)

Changing Landscape of Myeloma Therapy: Focus on Immunotherapy

Elisabet Esteve Manasanch (USA) (20 min)

Changing Landscape of Myeloma Therapy: Focus on Cell Therapy

Richard Champlin (USA) (20 min)

Management of Non-Secretory Myeloma

Jin Lu (China) (20 min)

Management of Bone Disease in Myeloma

Robert Orlowski (USA) (20 min)

12:30 PM ADJOURN

PLAN OF ACTION

Conference Announcement

1. Dedicated Conference Website for Registration and Information (www.aphcon.org/btg2017)
2. Pre-Conference Announcement Brochures
3. Announcements in Scientific Journals
4. Call for Abstracts
5. Advertising to the members of national and international hematologic societies including Hematology society of Singapore, Thailand, Australia, India etc
6. Email advertising to the members of the American Society of Hematology as well as local hematologic societies of the participating nations

Accommodations & Conference

Attendees will be offered subsidized group rate in various 4/ 5 Star Hotels close to the conference venue **(Swissôtel Le Concorde Hotel**. 204 Rachadapisek Road, Huay

Kwang ▪ Bangkok 10320 ▪ Thailand. Tel: +66 2694 2222 ▪ Fax: +66 2694

2218 ▪ E: reservation.bangkok@swissotel.com)

Transportation will be provided from the hotel to the conference for those not staying at the conference hotel

Transportation to and from airport (subsidized rates as well as hotel shuttles will be provided)

Visa and immigration assistance and info

Estimated Gathering

Approximately 300 Medical Professionals /Healthcare Providers

Invited Speakers / Chairpersons

Estimated 40 international and national experts (culled from a pool of ground-breaking researchers and practitioners) will address the congress.

Conference Registration

The registration fee to attend this conference includes three days of scientific sessions, continental breakfasts, lunches, conference dinner on Saturday, and corporate mini symposiums. Registration will open on September 15, 2016

Deadline Dates	Physicians and All Other Healthcare Professionals and Attendees**	Medical Students, Residents and fellows in training
October 25, 2016	\$ 399*	\$ 99
After October 25, 2016	\$ 499*	\$ 99
January 6, 2017	Online registration closes	
On-site registration	\$ 699*	\$ 199

Registration Deadline: January 6, 2017

Accompanying Guest Fee

*All registration fees to be paid in US Dollars

** Students, residents and fellows in training have to provide letter of support from their program director. Send registration request to shashik.vig@themedalgroup.com

Abstract Presentation

Meeting attendees are invited to submit clinical and basic science research abstract. At total of 100 abstracts will be selected for poster presentations. Two abstracts will be selected for oral presentation and award from the guest of honor on January 13, 2017.

Selected posters will be set up starting 7 am (January 13 and 14, 2017)

Poster viewing will take place during the breaks each day.

Posters will need to be taken down at the conclusion of the conference on Saturday, January 14, 2017.

Exhibit Booths

Selected vendors will be able to set up their exhibit booths to showcase informational materials, present a conduit for access for medical information for the meeting delegates as well as present with sales materials.

CORPORATE SUPPORT OPPORTUNITIES

BTG2017 invites industry supporters to participate during this prestigious event. Not only is this program the year's *best* Hematologic Malignancies conference, it also affords our industry partners the opportunity to interact with more than 500 of the leading physicians in the hematology/oncology field.

The **Commercial Support Program** for the **BTG2017** Conference enables corporations and other entities to enjoy maximum visibility at the meeting while demonstrating their support for the hematology/oncology community.

There are many opportunities for industry to support the conference's educational programs, annual meeting materials and services. Supporters may:

- Select a Support Opportunity from those listed on the following pages, and/or
- Sponsor an Independent Satellite Symposium, and/or
- Sponsor Spotlight Session
- Purchase Exhibit Space, and/or
- Provide General Support for the Educational Program.

The benefits enjoyed by the supporter are commensurate with the level of support as described in the following section. Each opportunity promises to provide a significant presence for companies during the conference.

Commensurate with the level of contribution, supporters are acknowledged in **BTG2017** meeting publications, on the conference website and as part of the program being supported. The planning committee, faculty and attendees alike appreciate the support of our commercial partners.

Without your contributions, educational events such as **BTG2017** would not be possible.

Support Packages

The **Platinum Package (US Dollar \$100,000.00)** is our most exclusive and comprehensive contributor opportunity. This high-profile opportunity provides your company with maximum exposure to the **BTG2017** hematology/oncology audience.

- Complimentary meeting space for a one hour mini-symposium (time slots will be allocated on a first come first serve basis)
- Complimentary meeting space for a three hour Advisory Board meeting focused on thought leader interactions (time slots will be allocated on a first come first serve basis)
- Complimentary Exhibit Booth
- Five complementary full conference registrations
- Three special invitations to the conference faculty dinner

Gold supporter (US Dollar \$75,000.00)

- Complimentary meeting space for a three hour Advisory Board meeting focused on thought leader interactions (Time slots will be allocated on a first come first serve basis)
- Complimentary Exhibit Booth
- Three complementary full conference registrations
- Three special invitations to the conference faculty dinner
- Acknowledgment of support on program announcement

Silver supporter (US Dollar \$50,000.00)

- Acknowledgement of being supporter of “Fellows in Training” or “Junior Faculty”
Conference Stipends for submitted abstract presenters
- Complimentary Exhibit Booth
- Two complementary full conference registrations
- Acknowledgment of support on program announcement
- Acknowledgment of support on final program announcement

Bronze supporter (US Dollar \$25,000.00)

Listing of your companies name in all conference materials acknowledging your support

- Complimentary Exhibit Booth
- One complementary full conference registration
- Acknowledgment of support on program announcement
- Listing of your companies name in all conference materials acknowledging your support

EXHIBIT BOOTH DETAILS

Exhibitors will have opportunity to

- Target influential decision makers
- Interact face-to-face with hematology professionals from APAC region
- Build visibility for your company in a competitive marketplace
- Expand your prospect base and strengthen existing customer relationships
- Introduce new products and services
- Generate new sales leads
- Give product demonstrations

Booth dimensions:

- 2m x 3m booth
- Company logo and description in the program guide
- Company listing on Premium Booth Signage and BTG2017 Website
- 1 x high counter, 2x bar stools, 1X discussion set
- 1x wastepaper basket, 2x shelving,
- 1x power point.

ORGANIZING PARTNER

The Medal Group Corp (3200 southwest freeway, suite 3300, Houston, Texas, USA 77027) is the official organizing partner for BTG2017. All payments and registration must be done through the Medal Group. Please refer all inquiries in this regards to Shashi Kanta at

Shashi.kanta@themedalgroup.com